I provide clinical development expertise to biotechnology companies in the field of Oncology drug development. The services I provide cater to the specific needs of the client and may range from high level strategic advice to protocol development and execution of a clinical program. Specially, I have the following experience:I have worked in all phases of drug development including multiple phase 3 studies and approvals. Most of my work over those years and especially as a consultant for the last 9 years has been in early drug development where I have driven clinical strategy, designed CDPs, written protocols, assembled investigators, gotten INDs across the finish line and run the phase 1 studies. On multiple occasions as an FTE (prior to becoming a consultant) I have had the good fortune of having developed highly active agents in phase and 1/2 and then designed the phase 3 registrational studies and led the NDA/BLA submission. Examples include cabozantinib, nilotinib (back up to Gleevec), and avastin in GBM. This mix of phase 1 and late stage development allows me to see a fuller picture with an end goal in sight. This I think makes me especially effective in assessing in-licensing opportunities.I have worked extensively in multiple therapeutic areas within oncology which include solid tumors (esp prostate), heme malignancies, bone metastases and osteoporosis and CNS malignanciesI have worked extensively across multiple therapeutic platforms which include small molecules (TKIs), biologics (antibodies and bispecifics), immuno-oncology, and cell therapy.As a consultant I do my very best to first determine what the needs of the client are and what their priorities may be. I then offer my advice and guidance accordingly within that framework. At the same time if I feel a client would benefit from hearing a dissenting opinion or alternate idea, I find a way to deliver that message in a respectful and honest manner.

I oversaw the global development of cabozantinib (XL184)